Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Missed TAKE Upsurge? RLS Spikes 7.9%, Ready to Explode After Descending Channel Escape: Analyst

Missed TAKE Upsurge? RLS Spikes 7.9%, Ready to Explode After Descending Channel Escape: Analyst

BlockchainReporterBlockchainReporter2026/02/14 17:12
By:BlockchainReporter

For crypto traders who missed the huge 250% surge on the Overtake (TAKE) coin, market analyst BitcoinHabebe urges them not miss the same opportunities currently being offered by the Rayls (RLS) token.

Overtake (TAKE) is a cryptocurrency of Overtake, a decentralized peer-to-peer marketplace built on the Sui network, which allows users to trade in-game items and various financial assets with ease. On the other hand, Rayls (RLS) is a DeFi token powering Rayls, an institutional-grade blockchain network that bridges traditional finance (especially institutions) with decentralized finance (DeFi).

If you missed 250% on $TAKE DO NOT MISS $RLS.

Same pattern
Same chart
Same price action

— BitcoinHabebe (@Bitcoinhabebe)

Overtake Riding Bullish Momentum

Since savvy crypto investors frequently keep their eyes on the larger crypto market, they’ve probably noticed Overtake’s recent surges. TAKE witnessed a massive price surge of 250% over the past week, and also today recorded another 53.7% upside move, making its price currently trade at $0.05548. The recent and ongoing climbs prompted curiosity among people about this cryptocurrency’s future capability.

However, that is not the only top-performing crypto asset in the digital asset market, as the analyst identified that the Rayls (RLS) token is primed to present the same massive gains soon. Based on his technical analysis, BitcoinHabebe identified that both Overtake and Rayls display the same patterns, charts, and price actions in their weekly charts.

As per the weekly timeframe shared by the analyst, TAKE has recently printed massive moves, breaking out from its descending channel pattern, suggesting an imminent bullish reversal. The asset had been trading within a descending channel, recognized by lower highs and lower lows, displaying a downtrend. However, its recent upside movement, noted recently by its sharp 24-hour and weekly rises of 53.7% and 250%, respectively, enabled the asset to break out of this bearish channel, pointing out a change in momentum from bearish to bullish.

The breakout was supported by a massive 180.95% increase in trading volume (according to data from CoinMarketCap), indicating investors are significantly engaging in trading activity in the market, reinforcing stronger user enthusiasm. This rise has built the foundation for a greater potential uptrend in the coming days.

Missed TAKE Upsurge? RLS Spikes 7.9%, Ready to Explode After Descending Channel Escape: Analyst image 0 The current price of Overtake is $0.05820.

Rayls On Breakout, Follows Overtake Pattern

As identified by the analyst, Rayls is also displaying the same classic bullish flag pattern printed by the Overtake coin (as illustrated above), suggesting a looming RLS price surge. RLS price has been down 7.4% and 43.2% over the past week and monthly respectively, indicating its consolidation movement within a descending channel. However, today, the token witnessed a remarkable 7.9% jump, which makes its price currently stand at $0.005347 (as per CoinGecko data), meaning investors are progressively entering the market, positioning themselves for higher growth.

As recognized by the analyst, Rayls is following Overtake’s bullish pattern, currently in the process of breaking out of a clear descending channel, suggesting potential for significant upside movement soon. With their recent price surges and breakouts, both Overtake and Rayls provide investors with exacting opportunities, especially for traders seeking to take advantage of looming market momentum.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23